RxDoctor Payments Data

Jennifer Buckingham

Family · Lumberton, NJNPI 1598160368

Payments from drug & device makers

$4,396in general payments, 2019–2025

Across 283 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$702
  • Biogen$451
  • Bristol Myers Squibb$430
  • Pfizer$357
  • UCB, Inc.$311
  • Lilly USA, LLC$227
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,376100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,396 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$54,769
Medicare patients
267
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate13$73,056
Lacosamide48$5,849
Memantine Hcl151$4,866
Levetiracetam157$4,745
Carbamazepine ErCarbamazepine27$3,752
Levetiracetam ErLevetiracetam17$2,318
Memantine Hcl ErMemantine Hcl18$2,254
Pregabalin21$2,092
Donepezil Hcl152$1,562
Gabapentin62$1,440
RizatriptanRizatriptan Benzoate54$1,378
Carbidopa-LevodopaCarbidopa/Levodopa58$1,083
Topiramate51$1,023
Primidone22$619
ClopidogrelClopidogrel Bisulfate43$614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$87$73,05613 claims
Upsher-smith Laboratories LLCTopiramate$55$1,02351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Lumberton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →